Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications.
Department of Dermatology, Division of Pediatric Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. ychiu@mcw.edu
Yvonne E
YE
Chiu
Beth A
BA
Drolet
Francine
F
Blei
Manuel
M
Carcao
Jason
J
Fangusaro
Michael E
ME
Kelly
Alfons
A
Krol
Sabra
S
Lofgren
Anthony J
AJ
Mancini
Denise W
DW
Metry
Michael
M
Recht
Robert A
RA
Silverman
Wynnis L
WL
Tom
Elena
E
Pope
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D002675:Child, Preschool; D005260:Female; D006390:Hemangioendothelioma / Q000188:drug therapy* / Q000473:pathology; D006391:Hemangioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D059885:Kasabach-Merritt Syndrome / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D011433:Propranolol / Q000008:administration & dosage*; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000319:Adrenergic beta-Antagonists; D011433:Propranolol